Inflammatix scores BARDA contract for infection tests

By staff writers

November 14, 2019 -- Startup Inflammatix is set to get $6 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) and up to $72 million as part of a cost-sharing contract to develop its rapid point-of-care (POC) tests for infections.

Rendering of the HostDx Fever test
Rendering of the HostDx Fever test, which will deliver rapid results at the point of care. Image courtesy of Inflammatix.

Burlingame, CA-based Inflammatix developed the HostDx multiplex isothermal platform for mRNA testing at the point of care, with results available in less than 30 minutes. BARDA is part of the U.S. Department of Health and Human Services.

In the first phase of the contract, the focus will be on developing Inflammatix's HostDx Fever test, which is designed to determine whether an infection is caused by a bacterium or virus based on gene expression patterns in the immune system, thereby helping to guide treatment and minimize the unnecessary use of antibiotics. The fever test requires a finger-stick blood sample.

In a statement, Inflammatix said the cash infusion will help it get the fever test into the clinic. Per the deal, BARDA also has options to partner on Inflammatix's HostDx Sepsis, which is also a blood test, and HostDx Fever Flu, a test of nasal swab samples. The sepsis test -- the company's most advanced product -- won the Disruptive Technology Award at the American Association for Clinical Chemistry (AACC) annual meeting in August.

Accelerate builds case for phenotypic susceptibility testing
Accelerate Diagnostics presented additional data from clinical studies supporting its Accelerate Pheno system with PhenoTest blood culture kit for susceptibility...
USPSTF maintains status quo on asymptomatic bacteriuria screening
The U.S. Preventive Services Task Force (USPSTF) essentially has reaffirmed its previous guidance on asymptomatic bacteriuria screening. In a recommendation...
Why blood cultures must come first in suspected sepsis
Patients suspected of having sepsis must get blood cultures prior to antibiotic therapy, in line with national guidelines, according to a study published...
T2 Biosystems advances new tests through BARDA funding
T2 Biosystems is accelerating the development of new direct-from-blood tests through a milestone-based funding contract with the U.S. Biomedical Advanced...
AACC: Inflammatix sepsis test wins Disruptive Technology contest
ANAHEIM, CA - A blood test for sepsis developed by California startup Inflammatix beat out products from two other companies to win the Disruptive Technology...

Copyright © 2019

Last Updated np 1/10/2020 11:44:26 AM